Filippo Milano, MD, PhD

/content/dam/www/faculty-photos/M/filippo-milano/filippo-milano.jpg
Dr. Filippo Milano MD, PhD
faculty member

Filippo Milano, MD, PhD

Associate Professor, Translational Science and Therapeutics Division, Fred Hutch

Associate Professor
Translational Science and Therapeutics Division, Fred Hutch

Director, Cord Blood Transplant Program, Fred Hutch

Director, Cord Blood Transplant Program
Fred Hutch

Fax: 206.667.2324
Mail Stop: MD-B306

Dr. Filippo Milano is a physician-scientist whose research is focused on the use of umbilical cord blood as a source of stem cells for transplantation to treat blood cancers. He concentrates on clinical practice improvements with a goal of increasing the number of patients eligible for transplantation and to improve clinical outcomes for those who receive cord blood transplants. He has carried out pivotal analyses of blood cancer patients who have received transplants, comparing outcomes of cord blood recipients with those who had blood stem cell transplants from unrelated donors. Dr. Milano also studies the use of an experimental, off-the-shelf cord blood product designed to extend immunological protection to recipients of cord blood transplants until their donated cells are fully engrafted and proliferating.

Other Appointments & Affiliations

Associate Professor, Division of Hematology and Oncology, University of Washington School of Medicine

Associate Professor, Division of Hematology and Oncology
University of Washington School of Medicine

Education

Fellowship: Hematology, University La Sapienza and University of Washington

Residency: Internal Medicine, University La Sapienza

PhD, University La Sapienza

MD, University La Sapienza

Current Projects

Impact of Non HLA-matched off-the-shelf ex-vivo expanded cord blood progenitors on outcomes in patients undergoing cord blood transplantation

Use of Non HLA-matched off-the-shelf ex-vivo expanded cord blood progenitors for patients with HIV undergoing cord blood transplantation

Evaluation of the use of Treosulfan as part of the conditioning regimen in patients undergoing cord blood transplantation and haploidentical transplant

Use of TCR gene therapy to cure viral infections in patients undergoing cord blood transplantation

Use of a new molecule (UM171) to expand cord blood progenitors